enozertinib — Initial data
2H 2026
Anticipate rinzimetostat program update in 2H 2026 and enozertinib clinical updates in 2H 2026 ahead of potential initiation of a registrational trialSource filing
ORIC biotech catalysts & pipeline
ORIC PHARMACEUTICALS INC · Data as of 2026-10-25
Upcoming catalysts
enozertinib — Conference presentation
Oct 26
Enozertinib (ORIC-114), a Brain Penetrant, Highly Selective EGFR Inhibitor, in Treatment-Naive Metastatic NSCLC with EGFR Atypical Mutations Presentation Number: 2627P Session Date & Time: Monday, October 26, 2026; 12:00 – 12:45 p.m. CET Session Title: Metastatic NSCLCSource filing